Crizotinib
- Generic Name
- Crizotinib
- Brand Names
- Xalkori
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22Cl2FN5O
- CAS Number
- 877399-52-5
- Unique Ingredient Identifier
- 53AH36668S
- Background
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusio...
- Indication
Crizotinib is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. Crizotinib is also indicated for the treatment of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory Anaplastic Large Cell Lymphoma, Recurrent Inflammatory Myofibroblastic Tumors, Refractory Inflammatory Myofibroblastic Tumors, Relapsed Anaplastic Large Cell Lymphoma, Unresectable Inflammatory Myofibroblastic Tumors
- Associated Therapies
- -
A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 187
- Registration Number
- NCT02838420
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Guangdong General Hospital, Guangzhou, China
🇨🇳Shanghai chest hospital, Shanghai, China
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 152
- Registration Number
- NCT02836847
- Locations
- 🇨🇳
Xinhua Hospital, Shanghai, Shanghai, China
Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
- Conditions
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT02824094
- Locations
- 🇯🇵
Hyogo Cancer Center, Akashi, Hyogo, Japan
🇯🇵Aichi cancer center central hospital, Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Interventions
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Xcovery Holdings, Inc.
- Target Recruit Count
- 290
- Registration Number
- NCT02767804
- Locations
- 🇪🇸
Hospital Vall d'Hebrón, Barcelona, Spain
🇪🇸Hospital Son Ltatzer, Palma de Mallorca, Spain
🇦🇷Sanatorio Parque S.A., Rosario, Argentina
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
- Conditions
- Interventions
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 152
- Registration Number
- NCT02761057
- Locations
- 🇺🇸
Pali Momi Medical Center, 'Aiea, Hawaii, United States
🇺🇸Queen's Cancer Center - Pearlridge, 'Aiea, Hawaii, United States
🇺🇸Illinois CancerCare-Peru, Peru, Illinois, United States
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
- Conditions
- Interventions
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Ariad Pharmaceuticals
- Target Recruit Count
- 275
- Registration Number
- NCT02737501
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇦🇺Monash Medical Centre, Bentleigh East, Victoria, Australia
🇦🇹Universitatsklinium St. Polten, Sankt Polten, Lower Austria, Austria
Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 692
- Registration Number
- NCT02679170
- Locations
- 🇪🇸
Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
🇪🇸Hospital Virgen de los Lirios, Alcoi, Alicante, Spain
🇪🇸Hospital Universitario de La Princesa, Madrid, Spain
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 423
- Registration Number
- NCT02664935
- Locations
- 🇬🇧
Royal Devon and Exeter Hospital, Exeter, United Kingdom
🇬🇧University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
🇬🇧Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02638428
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 8
- Registration Number
- NCT02612194
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.